Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2017

05.09.2016 | Original Article

Quality control of involved field radiotherapy in the HD 13 and HD 14 trials

Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)

verfasst von: J. Kriz, C. Baues, R. Engenhart-Cabillic, U. Haverkamp, K. Herfart, P. Lukas, A. Plütschow, H. Schmidberger, S. Staar, M. Fuchs, A. Engert, Prof. Dr. H. T. Eich

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

As part of the foundation of the German Hodgkin Study Group (GHSG) in 1978, a central radiotherapy (RT) reference centre was established to evaluate and to improve the quality of treatment. During the study generations, the quality assurance programs (QAP) were continued and adapted to the demands of each study. The purpose of this article is to demonstrate the results of the fifth study generation and to compare them to the previous findings.

Methods

With the start of the fourth GHSG study generation (HD10–12), a central prospective review of all diagnostic images was established to create an individual treatment plan for each early stage study patient. The quality of involved field RT was retrospectively evaluated by an expert panel of radiation oncologists. In the fifth study generation (HD13–15), the retrospective review of radiotherapy performed was refined and the results were compared with the findings of the fourth generation.

Results

The expert panel analyzed the RT planning and application of 1037 (28 %) patients (HD13 n = 465, HD14 n = 572). Simulation films were available in 85 % of cases and verification films in 87 %. RT was assessed as major violation in 46 % (HD13 = 38 %, HD14 = 52 %), minor violation in 9 % (HD13 = 9 %, HD14 = 9 %) and according to the protocol in 45 % (HD13 = 52 %, HD14 = 38 %).

Conclusion

The value for QAP of RT within the GHSG trials is well known. Still there were several protocol violations. In the future, the QAP program has to be adapted to the requirements of “modern RT” in malignant lymphoma.
Literatur
1.
Zurück zum Zitat Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652CrossRefPubMed Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652CrossRefPubMed
2.
Zurück zum Zitat Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206CrossRefPubMed Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206CrossRefPubMed
3.
Zurück zum Zitat Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with earlystage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608CrossRefPubMed Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with earlystage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608CrossRefPubMed
4.
Zurück zum Zitat Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410CrossRefPubMed Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410CrossRefPubMed
5.
Zurück zum Zitat Specht L, Yahalom J, Illidge T et al (2014) Modern radiotherapy for Hodgkin lymphoma – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862CrossRefPubMed Specht L, Yahalom J, Illidge T et al (2014) Modern radiotherapy for Hodgkin lymphoma – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862CrossRefPubMed
6.
Zurück zum Zitat Müller RP, Eich HT (2005) The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol 181(9):557–566CrossRefPubMed Müller RP, Eich HT (2005) The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol 181(9):557–566CrossRefPubMed
7.
Zurück zum Zitat Duhmke E, Diehl V, Loeffler M et al (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310CrossRefPubMed Duhmke E, Diehl V, Loeffler M et al (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310CrossRefPubMed
8.
Zurück zum Zitat Eich HT, Engenhart-Cabillic R, Hansemann K et al (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin’s lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71(5):1419–1424CrossRefPubMed Eich HT, Engenhart-Cabillic R, Hansemann K et al (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin’s lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71(5):1419–1424CrossRefPubMed
9.
Zurück zum Zitat Eich HT, Gossmann A, Engert A et al (2007) A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s Lymphoma – analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69(4):1187–1192CrossRefPubMed Eich HT, Gossmann A, Engert A et al (2007) A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s Lymphoma – analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69(4):1187–1192CrossRefPubMed
10.
Zurück zum Zitat Kriz J, Reinartz G, Dietlein M et al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 92(1):46–53CrossRefPubMed Kriz J, Reinartz G, Dietlein M et al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 92(1):46–53CrossRefPubMed
11.
Zurück zum Zitat Behringer K, Goergen H, Hitz F et al (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385:1418–1427CrossRefPubMed Behringer K, Goergen H, Hitz F et al (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385:1418–1427CrossRefPubMed
12.
Zurück zum Zitat von Tresckow B, Plütschow A, Fuchs M et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907–913CrossRef von Tresckow B, Plütschow A, Fuchs M et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907–913CrossRef
13.
Zurück zum Zitat Eich HT, Staar S, Gossmann A et al (2004) Centralized radiation oncologic review of cross-sectional imaging of Hodgkin’s disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 58(4):1121–1127CrossRefPubMed Eich HT, Staar S, Gossmann A et al (2004) Centralized radiation oncologic review of cross-sectional imaging of Hodgkin’s disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 58(4):1121–1127CrossRefPubMed
14.
Zurück zum Zitat Kriz J, Bangard C, Haverkamp U et al (2012) Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group. Strahlenther Onkol 188(8):660–665CrossRefPubMed Kriz J, Bangard C, Haverkamp U et al (2012) Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group. Strahlenther Onkol 188(8):660–665CrossRefPubMed
15.
Zurück zum Zitat Aleman B, Girinsky T, Maazen R et al (2005) Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 63(4):1184–1190CrossRefPubMed Aleman B, Girinsky T, Maazen R et al (2005) Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 63(4):1184–1190CrossRefPubMed
16.
Zurück zum Zitat Kinzie JJ, Hanks GE, MacLean CJ et al (1983) Patterns of care study: Hodgkin’s disease relapse rates and adequacy of portals. Cancer 52:2223–2226CrossRefPubMed Kinzie JJ, Hanks GE, MacLean CJ et al (1983) Patterns of care study: Hodgkin’s disease relapse rates and adequacy of portals. Cancer 52:2223–2226CrossRefPubMed
17.
Zurück zum Zitat Hoppe RT, Hanlon AL, Hanks GE et al (1994) Progress in the treatment of Hodgkin’s disease in the United States, 1973 versus 1983. The patterns of care study. Cancer 74(12):3198–3203CrossRefPubMed Hoppe RT, Hanlon AL, Hanks GE et al (1994) Progress in the treatment of Hodgkin’s disease in the United States, 1973 versus 1983. The patterns of care study. Cancer 74(12):3198–3203CrossRefPubMed
18.
Zurück zum Zitat Hughes DB, Smith AR, Hoppe R et al (1995) Treatment planning for Hodgkin’s disease: a patterns of care study. Int J Radiat Oncol Biol Phys 33(2):519–524CrossRefPubMed Hughes DB, Smith AR, Hoppe R et al (1995) Treatment planning for Hodgkin’s disease: a patterns of care study. Int J Radiat Oncol Biol Phys 33(2):519–524CrossRefPubMed
19.
Zurück zum Zitat Raemaekers JM, André MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194CrossRefPubMed Raemaekers JM, André MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194CrossRefPubMed
20.
Zurück zum Zitat Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607CrossRefPubMed Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607CrossRefPubMed
21.
Zurück zum Zitat Lohr F, Georg D, Cozzi L et al (2014) Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: When should they be considered and which questions remain open? Strahlenther Onkol 190(10):868–871CrossRef Lohr F, Georg D, Cozzi L et al (2014) Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: When should they be considered and which questions remain open? Strahlenther Onkol 190(10):868–871CrossRef
22.
Zurück zum Zitat Kriz J, Spickermann M, Lehrich P et al (2015) Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma: comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol 191(9):717–725CrossRefPubMed Kriz J, Spickermann M, Lehrich P et al (2015) Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma: comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol 191(9):717–725CrossRefPubMed
Metadaten
Titel
Quality control of involved field radiotherapy in the HD 13 and HD 14 trials
Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)
verfasst von
J. Kriz
C. Baues
R. Engenhart-Cabillic
U. Haverkamp
K. Herfart
P. Lukas
A. Plütschow
H. Schmidberger
S. Staar
M. Fuchs
A. Engert
Prof. Dr. H. T. Eich
Publikationsdatum
05.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1036-2

Weitere Artikel der Ausgabe 2/2017

Strahlentherapie und Onkologie 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.